Justin Gaethje names final opponents before UFC retirement

“The Highlight” knows the clock is ticking.

Ultimate Fighting Championship (UFC) fan favorite Justin Gaethje will attempt to become a two-time UFC Lightweight interim champion next weekend when he collides with No. 5-rankedPaddy Pimblett at UFC 324 on Sat., Jan. 24, 2026, inside T-Mobile Arena in Las Vegas, Nevada.

Before landing another shot at UFC gold, Gaethje made it clear he wasn’t interested in continuing his career without meaningful opportunities. Thanks to his resume and body of work, he was prepared to walk away — but for now, he has unfinished business.

And he knows exactly who he wants next.

Speaking with Jon Anik on Paramount+, Gaethje was asked whether he sees himself having over or under two fights left in his career.

“Once I get this belt, I’m not going to stop,” Gaethje said. “I’m going to beat Paddy, I’m going to beat Ilia [Topuria], and then I gotta get Max [Holloway] back — I have to. I need him to beat Charles [Oliveira]. Well, actually it doesn’t matter because they both beat me, so I want either one of them. Those are the only two guys I have the opportunity to get back right now. That’s what I’m shooting for.”

Despite his confidence, Gaethje understands he’s operating on borrowed time and is far closer to retirement than a long-term title reign.

“Every single one of these is a traumatic life experience,” Gaethje told TNT Sports recently. “There’s no matching the high or the low of winning or losing in this sport. It kind of ruins other parts of life. But I’m so hungry, and I’ve never felt more alive than when I go in there. I will miss it when it’s gone. I think I truly love it more than most.”

“This isn’t the beginning,” Gaethje concluded. “I’m 37 years old. I’d be a fool to think we’re just getting started here. The end is near.”


For the current UFC 324 fight card and Paramount+ lineup click here.

Former Buccaneers RB offers honest thoughts on Bucky Irving partnership

Former Buccaneers RB offers honest thoughts on Bucky Irving partnership originally appeared on The Sporting News.
Add The Sporting News as a Preferred Source by clicking here.

The Tampa Bay Buccaneers‘ offense is stacked, which makes it even more surprising that the franchise missed the playoffs in 2025.

But one downside to having a stacked offense is that there is only one ball. So, on any given week, a player can be left out completely.

For running backs, it is even tougher. The receivers all need their targets, which leaves precious carries to the back. But with Rachaad White and Bucky Irving both needing touches, it was hard to get both the ideal number of carries.

With Bucky taking over the RB1 role, some thought a problem could be brewing between Irving and White.

But appearing on the Loose Cannons podcast, White squashed those rumors.

“I’m just gonna be honest, obviously, how I’m advocating for him is too, because I’m rooting for Buck,” White said. “Regardless of what people want to say, oh, they don’t like each other, he’s mad at Buck because this. Nah, I really want Bucky to be great and have a great career, just to be honest with you.”

Irving undisputed RB1 in 2026

While Bucky made that sort of transition in 2025, he was injured for a portion of the season.

But if he is healthy, there is no denying who the starting back will be. Especially with White now a free agent and set to test the market.

Granted, the Bucs still have Sean Tucker, but he is a restricted free agent, so we think the Bucs will bring him back on a cheap deal.

And if you enter the 2026 season with Irving and Tucker as your backs, you are in a good spot.

White has been a good soldier for Tampa Bay, but all good things come to an end. Granted, this end has been accelerated with Bucky’s emergence, but there’s no denying Rachaad did his part for the organization.

And as far as those rumors, he squashed them emphatically.

More Buccaneers news: 

Hornets to retire No. 30 jersey of long-time franchise player, broadcaster Dell Curry

Dell Curry is more than just a father and the guy who likes to golf with his sons Stephen and Seth — he’s an NBA legend in his own right.

Which is why the Hornets announced that on March 19, they will retire Curry’s No. 30 jersey. Curry spent 10 seasons as a player with the Charlotte Hornets, won Sixth Man of the Year with the team, and has now spent the last 17 years as the team’s color commentator.

“When I first came to Charlotte in 1988, the city embraced my family and me in a way I never expected,” Curry said in a statement. “I was blessed to join an organization that believed in me, play alongside teammates who would become life-long friends and compete in front of the most passionate fans in the NBA. I’m proud to continue being part of the Hornets organization and this community today. Having my jersey retired is an honor I never imagined, and I’m forever grateful to Rick and Gabe as well as the entire organization. Charlotte shaped so many meaningful moments in my life, and I’m humbled by this recognition.”

This is part of an effort by Hornets Co-Chairmen/owners Rick Schnall and Gabe Plotkin to grow the connection between the team and community, and as part of that the franchise’s history.

Dell Curry is a big part of that history. A 3-point sharpshooter, Curry was a key part of some of the best Hornets teams including three 50-plus win campaigns and four playoff appearances. Curry remains the team’s all-time leader in games played (701), and is second in points (9,839), field goals made (3,951) and 3-point field goals (929).

For a younger generation of Hornets fans, he has always been the color analyst on the broadcasts.

The jersey retirement will happen during a halftime ceremony on March 19, when Charlotte hosts Orlando.

Trae Young reportedly to be out past the All-Star break with right MCL, quad injuries

When the Trae Young to Washington trade went down, one of the big questions was how much Young would play for the Wizards this season. Washington has motivation not to be too good this season and Young is the kind of player who raises a team’s floor (at least) and wins games.

Young will remain out with right MCL and quad injuries through the All-Star break in a month, at which point he will be re-evaluated, reports Shams Charania of ESPN.

It doesn’t seem coincidental that this report comes out just as there were growing questions around the league about whether the Wizards were running afoul of the league’s player participation policy. Those are the rules the league put in place a few years ago to make sure star players are on the court — and Young, an All-Star the past four years, qualifies. Young had already returned from an MCL issue, and quad injuries don’t usually take very long to recover from.

The Hawks held Young out with that quad contusion prior to the trade, but the expectation was that, once traded, he would be instantly, almost miraculously healthy (as many other players have been in that situation over the years).

Except, the Wizards are not looking to win too much. Washington owes its first-round pick to New York, but it is top eight protected heading into what is expected to be a very good draft at the top. The Wizards currently have the fourth-worst record in the league, and, even if things go poorly with the lottery, they cannot lose their pick. Even if Washington enters the lottery with the fifth- or sixth-worst record, there is a greater than 96% chance it keeps the pick. However, get to the seventh-worst record or better and the Knicks suddenly start to feel a lot better. Young, as a guy who can just win a team games, can mess up their plans.

Injury or no, there have been “rumbles” that the Wizards might give Young a two-year contract extension, reports NBA insider Marc Stein at The Stein Line. Young has a player option for $48.9 million next season. If he is willing to waive it, the Wizards might offer him two years with more guaranteed money overall but less per season (two years, $70-$75 million). It’s something to watch.

As is when Young will actually step on the court for the Wizards.

Red Sox’s signing of Ranger Suárez adds a co-ace behind Garrett Crochet, marks a bold first move post-Bregman

At long last, the Boston Red Sox are on the board in free agency.

Just hours after Alex Bregman’s deal with the Chicago Cubs was made official, the Red Sox made their first major-league free-agent signing of the winter on Wednesday, agreeing to a five-year, $130 million deal with left-hander Ranger Suárez. Boston was the only MLB team that had yet to add to its big-league roster via free agency this winter, with its additions to this point (notably, Sonny Gray, Willson Contreras and Johan Oviedo) all coming via trade. Suárez represents Boston’s biggest move yet — and a fascinating and unexpected pivot in the wake of losing Bregman.

Once Bregman bolted for Chicago, it was natural to speculate about how the Red Sox would attempt to replace his bat, despite a narrow selection of alternatives still available in free agency or via trade. But while the Red Sox have been linked to infielder Bo Bichette, reports indicated that Boston was contemplating leaning further into its pitching staff as its core strength, rather than trying to backfill Bregman’s impact on offense. It’s possible that Boston will still make an offensive addition to offset the loss of Bregman, but this agreement with Suárez suggests that a pitching-first strategy has indeed been activated. It’s also a sudden jolt in a starting pitching market that has largely laid dormant, and it could spark action involving the other top available arms, such as Framber Valdez and Zac Gallen.

At the outset of the offseason, Red Sox chief baseball officer Craig Breslow was not shy about his intention to add impact starting pitching. “I don’t think we’re going to spend a ton of time trying to add a No. 4, a No. 5 starter,” he said at the GM meetings in November. “If we’re going to make a starting pitching addition, I think it should be somebody who can pitch at the front of a rotation … particularly someone that we feel like can pitch alongside or slot in behind Garrett [Crochet] and start a playoff game for us.”

A few weeks later, the Red Sox acquired veteran right-hander Sonny Gray from the Cardinals, a highly accomplished arm but not one who necessarily fit Breslow’s description. Gray proved to be effective during his St. Louis tenure, and his hefty $31 million salary is commensurate with that of a frontline arm, but as he enters his age-36 season, he projects more as a reliable mid-rotation option than someone you’d feel confident giving the ball to in October. A few weeks later, the Sox added Johan Oviedo from Pittsburgh to strengthen their rotation depth further, but once Boston turned its focus to retaining Bregman, any discussion about the rotation was largely put on the back burner.

Evidently, Bregman’s exit prompted an urgent reexamination of the pitching situation; it does not seem like an accident that this pivot to Suárez happened so quickly after Bregman departed. Was this the plan all along, based on the knowledge that Bregman might leave? Or was this strictly reactive to the situation in which Boston unexpectedly found itself? Either way, what matters now is that Suárez is Boston-bound, and his candidacy to be the co-ace behind Crochet is certainly compelling, if unusual in some respects.

 [Get more Boston news: Red Sox team feed

We don’t know whether Breslow had Suárez in mind when he mentioned wanting someone who “could start a playoff game” for the Red Sox, but it’s easy to envision the left-hander’s postseason track record standing out as an alluring feature of his résumé. His 1.48 ERA is the fourth-lowest in MLB history among pitchers who have made at least seven playoff starts with at least 40 total innings pitched, behind only Sandy Koufax, Christy Mathewson and Stephen Strasburg. And perhaps his most memorable October outing came in relief, when he closed out the 2022 NLCS to win the pennant for the Phillies, the only organization he has ever known, having signed as a teenager out of Venezuela back in 2012.

Suárez has excelled in the regular season as well. While he lacks the kind of workload typically associated with pitchers who have commanded nine-figure deals — particularly compared to the two best starters available this winter, Dylan Cease and Framber Valdez — Suárez has been reliably effective when on the mound: Over the past five seasons, he ranked 15th in fWAR despite ranking 38th in innings pitched, and his career-high workload came last year, when he threw 157⅓ frames across 26 starts. Recurring back injuries cost Suárez time in three of the past five seasons, which is something to monitor as he ages.

The stellar stats speak for themselves and paint a picture of a worthy new co-star atop the Boston rotation. The stuff, however, contrasts sharply to that of Suárez’s new rotationmate. Whereas Crochet is one of baseball’s hardest-throwing pitchers, Suárez’s average fastball velocity on both his four-seamer (91.3 mph) and sinker (90.1 mph) is among the lowest of any rotation arm in the league. And his velo has trended down recently, with his 2025 averages a couple ticks less than the 93 mph he averaged on both heaters from 2021 to 2023.

Viewed favorably, Suárez’s ability to rack up outs without premium velocity is a good sign of his advanced pitchability and the likelihood that he can maximize his repertoire as he ages. A more bearish outlook would stress the concern that if Suárez experiences any more of a significant velocity drop, he’s at risk of his fastballs becoming unplayable against the best hitters on the planet. 

Velo aside, with plus command of a bevy of offerings beyond his two fastballs — a terrific changeup and curveball, plus a cutter — it’s no surprise that Suárez’s track record of run prevention is strong, and he thrives on inducing weak, ground-ball contact rather than racking up whiffs. In short, he’s a really good pitcher, even if the aesthetic of his arsenal pales in comparison to that of the average frontline arm in 2026.

With this addition, a new round of “now what?” questions will swirl around the Red Sox, specifically involving their position-player group that remains both imbalanced and incomplete. Failing to retain Bregman — their top target this winter and also a main character amid a tumultuous past year for the franchise — was an organizational failure by any measure. But with a resolution finally reached, even if it wasn’t the one they were hoping for, the Red Sox can move forward in their effort to construct a contending team in 2026. Suárez is a bold first move of the post-Bregman era, and more are likely to come.

Red Sox’s signing of Ranger Suárez adds a co-ace behind Garrett Crochet, marks a bold first move post-Bregman

At long last, the Boston Red Sox are on the board in free agency.

Just hours after Alex Bregman’s deal with the Chicago Cubs was made official, the Red Sox made their first major-league free-agent signing of the winter on Wednesday, agreeing to a five-year, $130 million deal with left-hander Ranger Suárez. Boston was the only MLB team that had yet to add to its big-league roster via free agency this winter, with its additions to this point (notably, Sonny Gray, Willson Contreras and Johan Oviedo) all coming via trade. Suárez represents Boston’s biggest move yet — and a fascinating and unexpected pivot in the wake of losing Bregman.

Once Bregman bolted for Chicago, it was natural to speculate about how the Red Sox would attempt to replace his bat, despite a narrow selection of alternatives still available in free agency or via trade. But while the Red Sox have been linked to infielder Bo Bichette, reports indicated that Boston was contemplating leaning further into its pitching staff as its core strength, rather than trying to backfill Bregman’s impact on offense. It’s possible that Boston will still make an offensive addition to offset the loss of Bregman, but this agreement with Suárez suggests that a pitching-first strategy has indeed been activated. It’s also a sudden jolt in a starting pitching market that has largely laid dormant, and it could spark action involving the other top available arms, such as Framber Valdez and Zac Gallen.

At the outset of the offseason, Red Sox chief baseball officer Craig Breslow was not shy about his intention to add impact starting pitching. “I don’t think we’re going to spend a ton of time trying to add a No. 4, a No. 5 starter,” he said at the GM meetings in November. “If we’re going to make a starting pitching addition, I think it should be somebody who can pitch at the front of a rotation … particularly someone that we feel like can pitch alongside or slot in behind Garrett [Crochet] and start a playoff game for us.”

A few weeks later, the Red Sox acquired veteran right-hander Sonny Gray from the Cardinals, a highly accomplished arm but not one who necessarily fit Breslow’s description. Gray proved to be effective during his St. Louis tenure, and his hefty $31 million salary is commensurate with that of a frontline arm, but as he enters his age-36 season, he projects more as a reliable mid-rotation option than someone you’d feel confident giving the ball to in October. A few weeks later, the Sox added Johan Oviedo from Pittsburgh to strengthen their rotation depth further, but once Boston turned its focus to retaining Bregman, any discussion about the rotation was largely put on the back burner.

Evidently, Bregman’s exit prompted an urgent reexamination of the pitching situation; it does not seem like an accident that this pivot to Suárez happened so quickly after Bregman departed. Was this the plan all along, based on the knowledge that Bregman might leave? Or was this strictly reactive to the situation in which Boston unexpectedly found itself? Either way, what matters now is that Suárez is Boston-bound, and his candidacy to be the co-ace behind Crochet is certainly compelling, if unusual in some respects.

 [Get more Boston news: Red Sox team feed

We don’t know whether Breslow had Suárez in mind when he mentioned wanting someone who “could start a playoff game” for the Red Sox, but it’s easy to envision the left-hander’s postseason track record standing out as an alluring feature of his résumé. His 1.48 ERA is the fourth-lowest in MLB history among pitchers who have made at least seven playoff starts with at least 40 total innings pitched, behind only Sandy Koufax, Christy Mathewson and Stephen Strasburg. And perhaps his most memorable October outing came in relief, when he closed out the 2022 NLCS to win the pennant for the Phillies, the only organization he has ever known, having signed as a teenager out of Venezuela back in 2012.

Suárez has excelled in the regular season as well. While he lacks the kind of workload typically associated with pitchers who have commanded nine-figure deals — particularly compared to the two best starters available this winter, Dylan Cease and Framber Valdez — Suárez has been reliably effective when on the mound: Over the past five seasons, he ranked 15th in fWAR despite ranking 38th in innings pitched, and his career-high workload came last year, when he threw 157⅓ frames across 26 starts. Recurring back injuries cost Suárez time in three of the past five seasons, which is something to monitor as he ages.

The stellar stats speak for themselves and paint a picture of a worthy new co-star atop the Boston rotation. The stuff, however, contrasts sharply to that of Suárez’s new rotationmate. Whereas Crochet is one of baseball’s hardest-throwing pitchers, Suárez’s average fastball velocity on both his four-seamer (91.3 mph) and sinker (90.1 mph) is among the lowest of any rotation arm in the league. And his velo has trended down recently, with his 2025 averages a couple ticks less than the 93 mph he averaged on both heaters from 2021 to 2023.

Viewed favorably, Suárez’s ability to rack up outs without premium velocity is a good sign of his advanced pitchability and the likelihood that he can maximize his repertoire as he ages. A more bearish outlook would stress the concern that if Suárez experiences any more of a significant velocity drop, he’s at risk of his fastballs becoming unplayable against the best hitters on the planet. 

Velo aside, with plus command of a bevy of offerings beyond his two fastballs — a terrific changeup and curveball, plus a cutter — it’s no surprise that Suárez’s track record of run prevention is strong, and he thrives on inducing weak, ground-ball contact rather than racking up whiffs. In short, he’s a really good pitcher, even if the aesthetic of his arsenal pales in comparison to that of the average frontline arm in 2026.

With this addition, a new round of “now what?” questions will swirl around the Red Sox, specifically involving their position-player group that remains both imbalanced and incomplete. Failing to retain Bregman — their top target this winter and also a main character amid a tumultuous past year for the franchise — was an organizational failure by any measure. But with a resolution finally reached, even if it wasn’t the one they were hoping for, the Red Sox can move forward in their effort to construct a contending team in 2026. Suárez is a bold first move of the post-Bregman era, and more are likely to come.

What I Learned After Trying Out Every Exoskeleton at CES

We may earn a commission from links on this page.

While I was covering CES, the big consumer electronics show in Las Vegas, I gave myself a side quest: try on every exoskeleton I could find. I kept seeing them at booths and events, promising to help me walk farther without fatigue, or reach my athletic potential as I’m (judging from their marketing videos) sprinting up a mountain. I ended up testing six of them—four assisted me at the hip, one at the knee, and one at the ankle.

Exoskeletons first landed on my radar as I was considering products for the Best of CES awards. I was helping to judge “age tech”—devices designed to help people as they age—and devices that assist with mobility were potentially in the running. But I was skeptical about whether consumer exoskeleton technology was mature enough to be safe and reliable, and whether people would realistically find exoskeletons convenient enough to use. Those are still open questions. In the end, we didn’t include any exoskeletons among our finalists, although I wouldn’t rule out the possibility for future years. 

Many of the exoskeleton companies positioned their products as fitness tech, with companies like Ascentiz and Hypershell using images of hikers and athletes in their marketing. My colleague James Bricknell from CNET took a Hypershell exoskeleton for a hike on a nearby canyon trail during CES, and said that it helped him easily keep up with more experienced hikers. (I borrowed that exact exoskeleton from him when we ran into each other in CNET’s newsroom and took it out for some impromptu sprints in the hallway.)

First, since I know you all want to see what they looked like and hear how they felt, I’ll give you a tour of the ones I tried, ranked from my least to most favorite. Then, below, I’ll give some thoughts on whether I think exoskeletons are worthwhile, and what I learned after talking to an expert who uses medical grade exoskeletons for physical therapy in rehabilitation facilities.

Unimpressive: WiRobotics WIM-S ($1,905)


Credit: Beth Skwarecki

This minimalist unit from WiRobotics was the last one I tried before leaving CES, and I’m sorry to say it comes in last place in my ranking as well. By this point, I’d tried several other hip-based exoskeletons that fit well and provided a significant boost to my walking and stepping. I loved the slim profile and simple design of the WIM-S—that is, until I turned it on. I was led up and down a mini staircase in the WiRobotics booth a few times before it was time to hand over the device to the next person in line. The WIM-S just didn’t feel like it was doing much.


Credit: Beth Skwarecki

WiRobotics’ design keeps the device fully in front of your hips, pushing down on the front of your leg. It feels a bit like when you push your hand against your knee to help you stand up. The WIM-S isn’t available for sale in the U.S. yet, but goes for the equivalent of $1,905 in South Korea

I’m definitely feeling something: Sumbu ($1,199-$1,999)


Credit: Rena Goldman

I first tried a Sumbu exoskeleton at CES Unveiled, a media preview event that occurs a few days before the show officially opens. For the first time that week, but not the last, I had people help me strap a belt around my waist and then they tightened cuffs around my legs just above my knees. Walking around, I could feel the device helping to move my legs; jogging in place, I commented that it would be nice if I could try these on stairs. Good news! The company’s real booth would have stairs. 

I visited the booth later on, in CES’s “Eureka Park” area dedicated to startups. I walked up and down the provided mini stairs, and felt the exoskeleton helping me easily step up, even when I took the stairs two at a time. I also stepped up onto the top of the stair unit when I was standing next to it—three stairs tall, I think—slightly surprising the people at the booth. But the exoskeleton made it feel easy. 

To be totally honest, this exoskeleton and the next two I list (Ascentiz and Hypershell) all had a similar fit and feel. It’s tough to rank them against each other based on just a few minutes of testing for each, so take my conclusions with a grain of salt. 

Sumbu sells three models of exoskeletons: the lightweight S3 ($1,199), the more powerful S3 Pro ($1,499), and the “maximum power” S3 Ultra ($1,999).

Helping me run: Ascentiz ($1,499 and up)


Credit: Beth Skwarecki

Ascentiz makes a modular exoskeleton that can assist you at both the hip and the knee, but only the hip module was available for me to try. Hip exoskeletons seemed to be more popular; including Ascentiz, I tried four hip exoskeletons this week, and only found one each of knee and ankle exoskeletons (not including Ascentiz—you’ll see the knee exoskeleton I did try below). 

Each exoskeleton basically treats a joint of your body as a hinge. Your knee is a natural hinge joint; your hip can move in different directions, but when you’re wearing an exoskeleton, it only assists you in forward and backward motion—hip extension and flexion, to put it in terms a physical therapist or fitness trainer would recognize. Hip-based exoskeletons assist your glutes in straightening your hip and/or assist your hip flexors in raising your leg in front of you. 


Credit: Beth Skwarecki

Ascentiz wisely set up its booth at the edge of the show floor, near a set of steps and also near a not-too-crowded area where I could walk and jog. The exoskeleton helped me climb stairs, and then I took it back and forth for a couple of jogs and even attempted a sprint. It felt smooth and my movements felt natural, with the power assisting me at just the right time during each stride. 

Ascentiz is currently running a Kickstarter for funding, and lists prices on its website. The H1 (hip) module is going for $699 to $999, and will have a suggested retail price of $1,499 to $1,999 depending on whether you go for the “Pro” or “Ultra” model. The knee module (K1) covers both knees and costs about $100 more. The full set, with both hip and knee assistance, will sell for $2,499 to $3,399.

Sprinting around the hallways like a goofball: Hypershell X Ultra ($1,999)


Credit: Rena Goldman

As I mentioned above, I borrowed my CNET colleague James Bricknell’s Hypershell X Ultra unit for a quick spin around the conference halls. I was impressed at how much its “beast mode” helped me do step-ups onto a chair, so then I decided to see if it could help me jog…and then run…and then sprint. And then attempt some quick turns and stops to see if it could keep up. (This was the first hip-based exoskeleton I tried to run in.) 


Credit: Beth Skwarecki

To my surprise, it felt great. To be fair, the Ascentiz felt pretty good to run in, too. I didn’t have space to run in the Sumbu one. The Hypershell kept up with my movements and assisted seamlessly. The others would sometimes think I was taking a step when I was actually standing still; the Hypershell wasn’t as prone to these missteps. 

Unlike some of the other exoskeletons on this list, the Hypershell is already on the market, and that’s probably why its technology feels a bit more mature. (It claims to be the first consumer outdoor exoskeleton.) The Hypershell X Ultra goes for $1,999 and the company’s lowest-price model is the Hypershell Go, at $899.

Going easy on my knees: Skip Mo/Go ($4,999)


Credit: Beth Skwarecki

I found the Skip booth in the AARP’s AgeTech Collaborative section. There, I tried a version of its Mo/Go exoskeleton, which is built into a pair of pants and operates at the knee. The pants hide leg cuffs, which feel a bit like a medical knee brace. The motorized unit snaps onto the outside of the pants, so it looks like you’re wearing normal hiking pants but with a robot’s joint at the side of your knee. 

I had to change out of my jeans and into the special pants, and then I could snap on the motor and start climbing stairs and squatting. The feeling is different than on the hip exoskeletons, as you might imagine. The motor essentially acts as an extra quad muscle, helping to straighten my knee, and slowing me down as I’m descending stairs. 

I went up and down the stairs. I did some squats in place. I sat down on a low seat and stood back up again. Having been through knee pain and knee surgery in the past, I instantly understood why this product would be in demand (and why it was one of AARP’s picks). The other exoskeletons try to decelerate you on the way down stairs, but this one really works. Sitting down, the robot knees helped me gently settle, rather than having that “plop” at the end of the motion that we all probably do without thinking about it. 

I only ran a few steps, but the running didn’t feel great—you can tell it’s not meant for that motion, at least not yet. I didn’t find these as comfortable as the other exoskeletons I tried, because the cuffs were inside the pants. That meant I had them contacting my bare skin, where they got sweaty and seemed like they might chafe. It also wasn’t particularly easy to get the pants on—if I had mobility issues, I’d probably want help with that. The Skip representative mentioned that the exoskeleton can be removed from the pants and worn without them, which is probably what I’d do if I owned a pair.

Skip’s Mo/Go isn’t available yet, but you can place a pre-order on the device now, which will eventually cost $4,999.

Putting a spring in my step: Dephy’s Sidekick ($4,500)


Credit: Beth Skwarecki

This was both the first and nearly the last exoskeleton I tried at CES. I took it for a quick spin at Unveiled and visited the booth in Eureka Park for a longer try-on later in the week. 

Dephy calls its exoskeleton “powered footwear.” The Sidekick has two parts: a shoe with a carbon plate, and a robotic arm that hugs your shin just below the knee. Dephy worked with Nike, and both companies came up with their own version of the exoskeleton; you can see Nike’s version here, branded as “Project Amplify.” 

The shoes can be worn on their own, and they’re cushy—I kept hearing people compare them to Hokas. They were certainly more comfortable than my own beat-up Nikes that I was wearing to get around the show halls. There’s a connector on the back, and the robotic arm hooks into it. If the arm were to detach while you’re wearing it, it would fall behind you, rather than in front. 


Credit: Beth Skwarecki

The Dephy Sidekick assists your calf muscles in helping you walk. They don’t start to assist until you’ve walked several steps, but then I felt them lift my heel on every step. The device doesn’t help you lift your foot, but it does help you to flex your foot downward, pushing you forward as you walk. Dephy says it targeted this movement since the calf muscles are “unsung heroes” of walking, providing most of the energy. 

I took a few steps at Unveiled, and even did a sprint through the crowd. Running felt weird, but not necessarily bad. Later, taking a longer walk through Eureka Park, I could definitely believe that Dephy’s ankle-based exoskeleton would save me more work and fatigue than the hip-based models I mentioned earlier.

Overall this design felt the best thought-out and most comfortable of all the exoskeletons I tried. The places where it attached to my body were the shoe and a pad on the front of my shin—both very comfortable, and easily worn over my normal socks and pants. The device hooks on quickly, and the battery packs slip in and out without any fuss. 

I worried about the quick motion of the motor pulling me (or, hypothetically, an older person with mobility issues) off balance, but the way the device is programmed, that seems a lot less likely than I assumed. The motor only kicks in while you’re walking forward, and stops assisting when it detects a sideways, backward, or otherwise unexpected step. At one point I dodged around somebody’s dog in a cramped corner of the show floor, and the Sidekick stopped assisting for those few steps, then went right back to helping me move forward.

The Sidekick starts shipping later this month, and the starter pack, including the shoes, batteries, and a charger, costs $4,500. 

How useful are exoskeletons, really? 

Before I can say that exoskeletons are useful in the real world, I’d have to know that they work, that they’re worth the cost, and that they make sense for the people who are most likely to want them. 

Trying them on convinced me that they do, in fact, work. Five out of six (sorry, WiRobotics) gave assistance that felt helpful and useful. I wasn’t sure that they’d pass even this low bar, so I’m already impressed. 

Cost is a problem, though. Who is going to spend $1,000 to $5,000 for a little assistance in walking or hiking? Serious hikers and runners would probably rather train harder to handle tough terrain and spend the money on gear or coaching. People who don’t normally hike might enjoy keeping up with their friends, but what non-hiker is going to spend that kind of money on a hiking exoskeleton? 

I could definitely see exoskeletons in a rental market—borrow a Hypershell unit to hike up a scenic mountain on vacation, or wear Dephy’s powered footwear to stay on your feet longer in a theme park (remembering that you’d need to swap out the batteries once or twice during the day).

After trying the devices and frowning at the cost, my biggest question was whether exoskeletons could be useful for people with mobility issues due to disability or chronic health conditions. And to get a better sense of that, I talked to someone who has been working with exoskeletons in a medical setting for years.

How these consumer exoskeletons compare to medical devices

Amanda Clark, director of Good Shepherd Creates, is a physical therapist by training. Good Shepherd is a rehabilitation network that has been using exoskeletons in physical therapy for over 10 years, including the Ekso Bionics robotic suit used for physical therapy sessions, the Trexo Plus for children, and the ReWalk personal device that people can take home. 

These exoskeletons can help people to walk who may not have been able to walk on their own before, or who are recovering from strokes or brain or spinal cord injuries. The more steps you get in, the better your nervous system gets at learning how to balance and walk. 

Clark told me that the models that are used in rehab may cost a facility around $250,000, plus another 10% of that per year for maintenance. Typically a person needs a device like a walker or crutches to use them, and must have a person assisting them—such as a physical therapist at a rehab facility, or a family member in the case of the few personal exoskeletons that are now on the medical market. 

Getting an exoskeleton approved as a medical device takes a lot of time and money for the manufacturer, Clark explained. Medical devices need to undergo a type of FDA approval similar to that for drugs. The manufacturer has to show that they use good manufacturing processes, and they have to run clinical trials showing that the device is safe, and then that it is effective for a specific medical condition. 

That explains why the company reps I talked to were very careful to say that they made a “consumer” or “recreational” or “athletic” device, and not a medical device. But consumer devices can’t usually be covered by insurance, which puts a pretty big barrier in the way of access. People with disabilities and chronic conditions—especially if they have trouble working—usually don’t have a thousands of dollars to drop on devices like these. 

With the particular models I saw being so new, if I were in that position, I’d also be nervous about whether the devices work as promised, whether they’re safe, and whether the company would stay in business over the years to provide support in case anything goes wrong. 

But as a technology with room to grow, there’s definitely a possibility that these devices could become useful and worthwhile for people with mobility issues. Clark said she’s happy to see the technological progress that has been made to get these devices small and light enough to be wearable outside the clinic.

Still, she sees cost as a major barrier. “My challenge to these companies is: how do you create something that is user friendly, that is slim profile, that could really promote these changes in independence and quality of life—but at a price point or in a way that is accessible to them?”

That’s where I land as well. The technology is promising, but at the current price point, I’m not sure that they’re accessible to enough people with mobility issues, or worthwhile enough for athletes. But since the devices I tried are new to the consumer market, I’m looking forward to seeing if there are improvements in price and technology in the years to come.

The JBL Flip 6 Bluetooth Speaker Is Nearly Half Off Right Now

We may earn a commission from links on this page. Deal pricing and availability subject to change after time of publication.

JBL portable speakers are popular for two simple reasons: They sound great, and they stand the test of time. I’ve had my JBL Charge 3 for years, and it’s still thumping powerful beats just like when I first got it. If you get a chance to buy an older JBL speaker at a discount, you can rest assured you’re getting a quality product at a good price—and that’s what Woot is offering right now. You can currently pick up a new JBL Flip 6 at a 46% discount, bringing it to $69.95 (originally $129.95), the lowest price it has ever reached according to price tracking tools.

The JBL Flip 6 has been around since 2021 and was succeeded in 2025 by the JBL Flip 7; hence the massive discount you’re seeing right now. Like all portable JBL speakers, the Flip 6 produces powerful sound, with a booming bass sound signature. If you don’t like how it sounds out of the box, you can tweak it with the JBL companion app, the best audio app I’ve tested (and I’ve tested many). It’s user-friendly, has many practical features like a full EQ adjustable setting, and it allows you to connect to other JBL speakers with Aurocast.

This is a rugged outdoor speaker with an IP67 rating, meaning it’s water- and dust-proof, so you can take it with you on any outdoor adventure. It will deliver about 12 hours of battery, rechargeable via USB-C, but that number will vary depending on how loud you play it. There is no speakerphone or AUX connection, and it’s a mono channel unless you hook it up to other JBL speakers. It supports AAC and SBC codecs, but not AptX. You can learn more about it on PCMag’s 4.0 “excellent” review.

You won’t find a better speaker under $70 with as good a reputation or as strong a companion app. If you’re looking for a portable speaker with powerful bass at a great discount, the JBL Flip 6 is a great buy.